Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment

European Journal of Endocrinology

Volumn 161, Issue 1, 2009, Pages 163-169

  Ribeiro, Rogerio Silicani ^a   Abucham, Julio ^a  

^a Division of Endocrinology   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CLOMIFENE CITRATE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; ANTIESTROGEN; CLOMIFENE;

ADULT; ARTICLE; ASTHENOSPERMIA; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS; BONE DENSITY; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GLUCOSE BLOOD LEVEL; GONAD FUNCTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; PENIS ERECTION; PRIORITY JOURNAL; PROLACTINOMA; RECURRENT DISEASE; SEMEN ANALYSIS; SPERMATOZOON MOTILITY; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CONVALESCENCE; DRUG COMBINATION; DRUG EFFECT; ENERGY METABOLISM; ERECTILE DYSFUNCTION; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; BODY COMPOSITION; CLOMIPHENE; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; ENERGY METABOLISM; ERECTILE DYSFUNCTION; ESTRADIOL; ESTROGEN ANTAGONISTS; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGONADISM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; RECOVERY OF FUNCTION; SPERM MOTILITY; TESTOSTERONE; YOUNG ADULT;

EID: 67650709486     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0084     Document Type: Article

References (26)

1. Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534.
2. Hulting AL, Muhr C, Lundberg PO & Werner S. Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Medica Scandinavica 1985 217 101-109.
3. Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS & Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. Journal of Clinical Endocrinology and Metabolism 2000 85 3053-3057.
4. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrili S & Lombardi G. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Journal of Clinical Endocrinology and Metabolism 2004 89 1704-1711.
5. Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH, Hall K & Quinton R. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function. Pituitary 2002 5 243-246.
6. Chattopadhyay A, Bhansali A & Masoodi SR. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 2005 8 147-154.
7. Gillam MP, Middler S, Freed DJ & Molitch ME. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. Journal of Clinical Endocrinology and Metabolism 2002 87 4447-4451.
8. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS & Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2006 91 1995-2010.
9. Rhoden EL & Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. New England Journal of Medicine 2004 350 482-492.
10. Lim VS & Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. Journal of Clinical Endocrinology and Metabolism 1976 43 1370-1377.
11. Landefeld CS, Schambelan M, Kaplan SL & Embury SH. Clomiphene-responsive hypogonadism in sickle cell anemia. Annals of Internal Medicine 1983 99 480-483.
12. Bjork JT, Varma RR & Borkowf HI. Clomiphene citrate therapy in a patient with Laennec's cirrhosis. Gastroenterology 1977 72 1308-1311.
13. Tan RS & Vasudevan D. Use of clomiphene citrate to reverse premature andropause secondary to steroid abuse. Fertility and Sterility 2003 79 203-205.
14. Ronnberg L, Reinila M & Ylikorkala O. Effects of experimental hyperprolactinemia and clomiphene on pituitary responsiveness to LHRH and TRH in men. Andrologia 1985 117 364-368.
15. Vermeulen A, Verdonck L & Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism 1999 84 3666-3672.
16. Shepherd JA, Lu Y, Wilson K, Fuerst T, Genant H, Hangartner TN, Wilson C, Hans D & Leib ES; International society for clinical densitometry committee on standards of bone measurement. Cross-calibration and minimum precision standards for dualenergy X-ray absorptiometry: the 2005 ISCD Official Positions. Journal of Clinical Densitometry 2006 9 31-36.
17. Rhoden EL, Teloken C, Sogari PR & Vargas Souto CA. The use of the simplified international index of erectile function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. International Journal of Impotence Research 2002 14 245-250.
18. Fleck MP, Louzada S, Xavier M, Chachamovich E, Vieira G, Santos L & Pinzon V. Application of the Portuguese version of the abbreviated instrument of quality life WHOQOL-BREF. Revista de Saude Publica 2000 34 178-183.
19. Jimenez MA, Magee DE, Bryant HU & Turner RT. Clomiphene prevents cancellous bone loss from tibia of ovariectomized rats. Endocrinology 1997 138 1794-1800.
20. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS & Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. New England Journal of Medicine 1997 337 91-95.
21. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB & Korach KS. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. New England Journal of Medicine 1994 331 1056-1061.
22. Lamberts SW, Verleun T & Oosterom R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 1982 34 339-342.
23. Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF Jr & Hayes FJ. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. Journal of Clinical Endocrinology and Metabolism 2008 93 784-791.
24. Clark JH & Markaverich BM. The agonistic-antagonistic properties of clomiphene: a review. Pharmacology and Therapeutics 1981 15 467-519.
25. Moreira AC, Veríssimo JM, Foss MC, Iazigi N, Maciel LM, Pimenta WD, Rodrigues JA & Santoro JR. Pubertal maturation of the LH stimulatory response to clomiphene citrate in congenital virilizing adrenal hyperplasia. Clinical Endocrinology 1982 17 441-447.
26. Kulin HE, Grumbach MM & Kaplan SL. Gonadal-hypothalamic interaction in prepubertal and pubertal man: effect of clomiphene citrate on urinary follicle-stimulating hormone and luteinizing hormone and plasma testosterone. Pediatric Research 1972 6 162-171.